ISIde Smets

Ide Smets

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ide Smets has a total of 97 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Individual Variability of CD19 + B‐Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of Ocrelizumab

    by Laura Hogenboom, Lisa G. Schoof, Liza M. Y. Gelissen, Jop Mostert, Luuk van Rooij, Elske Hoitsma, Caspar E. P. van Munster, Jeroen van Eijk, Nienke F. Kalkers, Kirsten S. Adriani, et al.

    Background and Objectives: B‐cell repopulation patterns in ocrelizumab treated patients with multiple sclerosis are highly variable between individuals, but the course of B‐cell reoccurrence after subsequent doses within an individual is not yet determined. Our aim was to determine the intraindividual variability of CD19+ B‐cell repopulation after each ocrelizumab dose when using CD19+ B‐cell guided interval dosing. Methods: This was a prospective cohort study, as part of the ongoing BLOOMS trial, investigating participants randomised for B‐cell guided interval dosing of ocrelizumab with ≥ 2 dosing intervals. Coefficients of variation were calculated for time from last ocrelizumab dose to first CD19+ B‐cell measurement ≥ 0.01 × 10 9 cells/L. Results: Seventy‐five participants with a total of 209 B‐cell guided intervals were included. Time from last dose to first appearance of CD19+ B‐cell count ≥ 0.01 × 10 9 cells/L showed wide variability between individuals (20.6–72.1 weeks), but the median variation was 5.6% (IQR: 3.1–8.4) within an individual. This translated to a variation of 2 weeks per dosing interval on average. Discussion: Time to CD19+ B‐cell repopulation after each ocrelizumab dose is individually stable. This finding could pave the way for easier and more accessible future personalised interval dosing of B‐cell depleting therapies if this stability is confirmed in long‐term treatment.


  • Open Access

    Integrin β1 Demarks Precursors of Brain-Residing Antibody-Secreting Cells in Multiple Sclerosis

    by Kirsten L. Kuiper, Laurens Bogers, Jasper Rip, Yifan van Hasselt, Marie-José Melief, Annet F. Wierenga-Wolf, Romy A.M. Klein Kranenbarg, Eric Bindels, Harmen J.G. van de Werken, Janet de Beukelaar, et al.

    Multiple sclerosis (MS) is characterized by CXCR3+ memory B cells that infiltrate the CNS to mature into antibody-secreting cells (ASCs). It remains elusive how to benefit from this disease hallmark as a prognostic tool. We aimed to uncover markers that reflect B-cell entry and maturation in the CNS and, on that basis, explore associations with response to high-efficacy MS therapies. Ex vivo single-cell technologies were applied to blood samples and postmortem CNS suspensions from MS and control donors, either treated or untreated. In addition, in vitro assays were performed on blood samples from healthy individuals to functionally asses B-cell activation, differentiation, and transmigration. Single-cell RNA sequencing revealed ITGB1 (integrin β1/CD29) as a major discriminator of CXCR3+ memory B cells in blood, which was validated using spectral flow cytometry. CD29+CXCR3+ memory B cells preferentially crossed a brain microvascular endothelial layer and were highly receptive to T-cell help to become ASCs in vitro. In contrast to blood, CD29 and CXCR3 coexpression was restricted to ex vivo ASCs derived from CSF, meninges, and brain tissue of people with MS, which was supported by enhanced CD29 upregulation on in vitro-differentiated ASCs. While CD29 was downregulated on CXCR3+ memory B cells that accumulated in the blood of natalizumab-treated patients, CD29 levels were only reduced on CXCR3+ memory B cells that repopulated in cladribine-treated patients without early disease activity. These findings put forward CD29 as a putative marker on CXCR3+ precursors of CNS-residing ASCs for predicting treatment responses in MS.

  • Open Access

    Aggressive treatment of early acute focal inflammatory activity to extend the window for BTK inhibition in multiple sclerosis

    by Joost Smolders, Ide Smets, Beatrijs Wokke

    The development of novel therapy classes such as Bruton’s tyrosine kinase (BTK) inhibitors, which target disability progression independent of relapses and largely independent of new lesion formation, requires a reappraisal of strategies in the treatment of multiple sclerosis (MS). We argue that this novel class of treatment further emphasizes the need for early and aggressive treatment with classical disease-modifying compounds for the prevention of both relapses and new MRI lesion formation and their associated disability accrual. This will extend the window to recognize early progressive disability accumulation independent of acute focal inflammatory activity, and for people with MS to benefit from novel therapies such as BTK inhibition, which target damaging pathophysiological processes independent of peripherally driven focal inflammation.


  • Open Access

    Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model

    by Ide Smets, Matthijs Versteegh, Simone Huygens, Beatrijs Wokke, Joost Smolders

    Background: Uncertainty about disproportionate impact on health care budgets limits implementation of early highly effective treatment (EHT) in multiple sclerosis (MS). Objective: To estimate cost-effectiveness of escalation versus EHT disease-modifying treatment (DMT) sequences. Methods: Using a health-economic approach, we analysed health benefits (relapse rate reduction, disability prevention), direct/indirect DMT and societal costs of escalation versus EHT DMT sequences. In scenario analyses, we allowed (1) earlier use of alemtuzumab (ALE) and (2) a single retreatment with cladribine (CLA). Results: In our model, we showed that the ratio between costs and quality-adjusted life years (QALYs) for the most cost-effective EHT and escalation sequence results into a similar net health benefit with higher costs and also higher QALYs associated with an EHT versus escalation strategy. Earlier use of ALE is more cost-effective than in later lines, even when aggravating the impact of its side-effects tenfold. Retreatment with CLA was more cost-effective in both escalation and EHT sequences. Conclusions: Certain EHT sequences are equally cost-effective to escalation sequences and are likely to result in more health at uncertain additional costs. The favourable cost–benefit ratio of CLA and ALE suggests that a wider application of affordable highly effective therapies could promote the cost-effectiveness both EHT and escalation approaches.


  • Open Access

    Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model

    by Cato E.A. Corsten, Simone A. Huygens, Matthijs M. Versteegh, Beatrijs H.A. Wokke, Ide Smets, Joost Smolders


  • Open Access

    Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

    by Ide Smets, Matthijs Versteegh, Simone Huygens, Cato Corsten, Beatrijs Wokke, Joost Smolders

    Background: In high-income countries, four anti-CD20 monoclonal antibodies (mAbs) are used or in the pipeline for relapsing MS: ocrelizumab, ofatumumab (both registered), ublituximab (awaiting registration) and rituximab (off-label). List prices differ significantly between registered and off-label drugs. Objective: Comparing differences in benefits between anti-CD20 mAbs from a health-economic and societal perspective. Methods: To reflect lifetime use of DMTs, we used a treatment-sequence model to compare ocrelizumab/ofatumumab and eight other drug classes in terms of health (lifetime relapses, time to Expanded Disability Status Scale [EDSS] 6, lifetime quality-adjusted life years) and cost-effectiveness (net health benefit). To become cost-effective compared to ocrelizumab, we modelled the list price of ublituximab and desired effect on EDSS progression of rituximab. Results: Although drug sequences with ocrelizumab in first- and second-line were more cost-effective than ofatumumab, our probabilistic analysis suggests this outcome was very uncertain. To be more cost-effective than ocrelizumab, ublituximab needs to be about 25% cheaper whilst rituximab needs to equal the effect on disability progression seen with first-line treatments. Conclusions: Our model showed no clear difference in cost-effectiveness between ocrelizumab and ofatumumab. Hence, prescribing the least costly anti-CD20 mAb can democratise MS care without a loss in health benefits.


  • Open Access

    Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model

    by Cato E.A. Corsten, Simone A. Huygens, Matthijs M. Versteegh, Beatrijs H.A. Wokke, Ide Smets, Joost Smolders

    Background Three sphingosine-1-phosphate receptor (S1PR) modulators are currently available as disease-modifying therapies (DMTs) for relapsing MS in the Netherlands (i.e. fingolimod, ozanimod and ponesimod). We aimed to identify which S1PR modulator yields the highest benefit from a health-economic and societal perspective during a patient’s lifespan. Methods Incorporating Dutch DMT list prices, we used the ErasmusMC/iMTA MS model to compare DMT sequences, including S1PR modulators and eight other DMT classes, for treatment-naive patients with relapsing MS in terms of health outcomes (number of lifetime relapses, time to Expanded Disability Status Scale (EDSS) 6, lifetime quality-adjusted life years (QALYs)) and cost-effectiveness (net health benefit (NHB)). We estimated the influence of list price and EDSS progression on cost-effectiveness outcomes. Results In deterministic and probabilistic analysis, DMT sequences with ponesimod have lower lifetime costs and higher QALYs resulting in a higher average NHB compared to sequences with other S1PR modulators. Ponesimod remains the most cost-effective S1PR modulator when EDSS progression is class-averaged. Given the variable effects on disability progression, list price reductions could make fingolimod but not ozanimod more cost-effective than ponesimod. Conclusion Our model favours ponesimod among the S1PR modulators for the treatment of relapsing MS. This implies that prioritizing ponesimod over other S1PR modulators translates into a more efficacious spending of national healthcare budget without reducing benefit for people with MS. Prioritizing cost-effective choices when counselling patients contributes to affordable and accessible MS care. Highlights Disease-modifying therapies (DMTs) are the largest cost driver in MS Three sphingosine-1-phosphate receptor (S1PR) modulators are used for relapsing MS Our model compares sequences of up to 5 DMTs in terms of health (relapses, progression) and costs Comparing sequences including S1PR modulators, ponesimod is the most cost-effective drug Cost-effectiveness research helps to prioritize when prescribing drugs of a similar class

  • Open Access

    Should anti-CD20 be used as an immune reconstitution therapy?

    by Ide Smets, Beatrijs Wokke, Joost Smolders


  • Open Access

    Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis

    by K. Allen-Philbey, A. Stennett, T. Begum, Ac. Johnson, R. Dobson, G. Giovannoni, S. Gnanapavan, M. Marta, I. Smets, B.P. Turner, et al.